457 related articles for article (PubMed ID: 23521917)
1. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.
Shahabi V; Berman D; Chasalow SD; Wang L; Tsuchihashi Z; Hu B; Panting L; Jure-Kunkel M; Ji RR
J Transl Med; 2013 Mar; 11():75. PubMed ID: 23521917
[TBL] [Abstract][Full Text] [Related]
2. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Gosho M; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
J Dermatol Sci; 2017 Nov; 88(2):225-231. PubMed ID: 28736218
[TBL] [Abstract][Full Text] [Related]
3. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
4. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
Weber JS; Dummer R; de Pril V; Lebbé C; Hodi FS;
Cancer; 2013 May; 119(9):1675-82. PubMed ID: 23400564
[TBL] [Abstract][Full Text] [Related]
5. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
[TBL] [Abstract][Full Text] [Related]
6. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
[TBL] [Abstract][Full Text] [Related]
7. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies.
Nakamura Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M; Fujisawa Y
Jpn J Clin Oncol; 2019 May; 49(5):431-437. PubMed ID: 30753621
[TBL] [Abstract][Full Text] [Related]
8. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
9. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.
Bertrand A; Kostine M; Barnetche T; Truchetet ME; Schaeverbeke T
BMC Med; 2015 Sep; 13():211. PubMed ID: 26337719
[TBL] [Abstract][Full Text] [Related]
10. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
[TBL] [Abstract][Full Text] [Related]
11. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
[TBL] [Abstract][Full Text] [Related]
12. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
[TBL] [Abstract][Full Text] [Related]
13. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
16. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA; Kang N; Lee SJ; Hodi FS; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963015
[TBL] [Abstract][Full Text] [Related]
17. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
Almutairi AR; McBride A; Slack M; Erstad BL; Abraham I
Front Oncol; 2020; 10():91. PubMed ID: 32117745
[No Abstract] [Full Text] [Related]
18. Biomarkers on melanoma patient T cells associated with ipilimumab treatment.
Wang W; Yu D; Sarnaik AA; Yu B; Hall M; Morelli D; Zhang Y; Zhao X; Weber JS
J Transl Med; 2012 Jul; 10():146. PubMed ID: 22788688
[TBL] [Abstract][Full Text] [Related]
19. Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers.
Wang Y; Zou J; Li Y; Jiao X; Wang Y; Zhuo N; Gao M; Gong J; Li J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Li J; Li Y; Shen L; Zhang H; Lu Z
Front Immunol; 2022; 13():987568. PubMed ID: 36159840
[TBL] [Abstract][Full Text] [Related]
20. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
